Biodegradable Inorganic Nanovector: Passive Versus Active Tumor Targeting in SiRNA Transportation
Overview
Affiliations
The biodegradable inorganic nanovector based on a layered double hydroxide (LDH) holds great promise for gene and drug delivery systems. However, in vivo targeted delivery of genes through LDH still remains a key challenge in the development of RNA interference therapeutics. Here, we describe in vivo and in vitro delivery system for Survivin siRNA (siSurvivin) assembled with passive LDH with a particle size of 100 nm or active LDH conjugated with a cancer overexpressing receptor targeting ligand, folic acid (LDHFA), conferring them an ability to target the tumor by either EPR-based clathrin-mediated or folate receptor-mediated endocytosis. When not only transfected into KB cells but also injected into xenograft mice, LDHFA/siSurvivin induced potent gene silencing at mRNA and protein levels in vitro, and consequently achieved a 3.0-fold higher suppression of tumor volume than LDH/siSurvivin in vivo. This anti-tumor effect was attributed to a selectively 1.2-fold higher accumulation of siSurvivin in tumor tissue compared with other organs. Targeting to the tumor with inorganic nanovector can guide and accelerate an evolution of next-generation theranosis system.
Application and design considerations of ROS-based nanomaterials in diabetic kidney disease.
Huang Q, Tang J, Ding Y, Li F Front Endocrinol (Lausanne). 2024; 15:1351497.
PMID: 38742196 PMC: 11089164. DOI: 10.3389/fendo.2024.1351497.
Li L, Soyhan I, Warszawik E, van Rijn P Adv Sci (Weinh). 2024; 11(20):e2306035.
PMID: 38501901 PMC: 11132086. DOI: 10.1002/advs.202306035.
Assessing the Adjuvant Effect of Layered Double Hydroxides (LDH) on BALB/c Mice.
Govea-Alonso D, Garcia-Soto M, Mendoza-Perez E, Farfan-Castro S, Fuente D, Gonzalez-Ortega O Materials (Basel). 2023; 16(15).
PMID: 37570172 PMC: 10419364. DOI: 10.3390/ma16155467.
Current status of nano-vaccinology in veterinary medicine science.
Sadr S, Poorjafari Jafroodi P, Haratizadeh M, Ghasemi Z, Borji H, Hajjafari A Vet Med Sci. 2023; 9(5):2294-2308.
PMID: 37487030 PMC: 10508510. DOI: 10.1002/vms3.1221.
Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials.
Xu M, Han X, Xiong H, Gao Y, Xu B, Zhu G Molecules. 2023; 28(13).
PMID: 37446806 PMC: 10343932. DOI: 10.3390/molecules28135145.